Efficacy and safety of interferon and ribavirin therapy in HIV-HCV coinfected patients

被引：2
|
作者：
Zylberberg, H
Benhamou, Y
Chaix, ML
Fontaine, H
Rouzioux, C
Katlama, C
Poynard, T
Bréchot, C
Pol, S
机构：
[1] CHU Necker, INSERM, U370, Liver Unit,CHU Pitie Salpetriere, F-75015 Paris, France
[2] CHU Necker, INSERM, U370, Virol Lab,CHU Pitie Salpetriere, F-75015 Paris, France
来源：
JOURNAL OF HEPATOLOGY | 2000年 / 32卷
关键词：
D O I：
10.1016/S0168-8278(00)81007-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [11] Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects
    Genebat, Miguel
    Vera, Francisco
    Hernandez-Quero, Jose
    Domingo, Pere
    Guardiola, Jose M.
    Martinez-Madrid, Onofre
    Martinez, Lorena
    Garcia de la Liana, Francisco
    Sanchez-Villegas, Jorge
    Alvarez, Hortensia
    Marino, Ana
    Lluch, Jose F.
    Martinez-Perez, Maria A.
    Marin, Jorge
    Ruiz-Mateos, Ezequiel
    Leal, Manuel
    ANTIVIRAL RESEARCH, 2014, 104 : 59 - 61
  • [12] Predictive value of early virological response (12 weeks) to pegylated interferon plus ribavirin in HIV-HCV coinfected patients
    Perez-Olmeda, M
    Martin-Carbonero, L
    Romero, M
    Rios, P
    Nunez, M
    Soriano, V
    Garcia-Samaniego, J
    JOURNAL OF HEPATOLOGY, 2003, 38 : 163 - 163
  • [13] Hcv dynamics in HIV/HCV coinfected patients treated with pegylated interferon and ribavirin.
    Talal, AH
    Shata, MT
    Flynn, SM
    Dorante, G
    Laughlin, M
    Ribeiro, RM
    Perelson, AS
    HEPATOLOGY, 2002, 36 (04) : 205A - 205A
  • [14] Efficacy of safety of therapy with interferon alfa-2a plus ribavirin in HIV/HCV coinfected patients. Preliminary results of an open prospective study
    Galeras, JA
    Tural, C
    Force, L
    Montoliu, S
    de Castro, JAR
    Coll, S
    Fuster, D
    Barrufet, P
    Dominguez, MD
    Planas, R
    JOURNAL OF HEPATOLOGY, 2003, 38 : 142 - 142
  • [15] Early plasma exposure after a first dose of ribavirin in HIV-HCV coinfected patients compared with HCV monoinfected patients
    Hatu, Giorgiana
    Pradat, Pierre
    Pourcelot, Emmanuel
    Maynard-Muet, Marianne
    Bailly, Francois
    Miailhes, Patrick
    Zoulim, Fabien
    Gagnieu, Marie-Claude
    HEPATOLOGY, 2013, 58 : 1134A - 1134A
  • [16] Efficacy and tolerance of HCV treatment in HIV-HCV coinfected patients: The potential interaction of PI treatment
    Poizot-Martin, I
    Marimoutou, C
    Benhaim, S
    Drogoul-Vey, MP
    Dinh, T
    Vion-Dury, F
    Frixon-Marin, V
    Tamalet, C
    Gastaut, JA
    HIV CLINICAL TRIALS, 2003, 4 (04): : 262 - 268
  • [17] Extended Therapy With Pegylated Interferon and Weight-Based Ribavirin for HCV-HIV Coinfected Patients
    Chung, Raymond T.
    Umbleja, Triin
    Chen, Jennifer Y.
    Andersen, Janet W.
    Butt, Adeel A.
    Sherman, Kenneth E.
    HIV CLINICAL TRIALS, 2012, 13 (02): : 70 - 82
  • [18] Occult hepatitis B in HIV-HCV coinfected patients
    Piroth, Lionel
    Lafon, Marie-Edith
    Binquet, Christine
    Bertillon, Pascale
    Gervais, Anne
    Lootvoet, Enguerrand
    Lang, Jean-Marie
    De Jaureguiberry, Jean Pierre
    Chene, Genevieve
    Leport, Catherine
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2008, 40 (10) : 835 - 839
  • [19] Assessing liver disease in HIV-HCV coinfected patients
    Tsochatzis, Emmanuel A.
    Castera, Laurent
    CURRENT OPINION IN HIV AND AIDS, 2015, 10 (05) : 316 - 322
  • [20] Chronic hepatitis C in HIV-HCV coinfected patients
    Gervais, A
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2002, 26 : B121 - B132
12345